Posted on 21/12/2009 in Pharmaceutical Company Product News Almirall and its pharmaceutical partner Forest Laboratories have announced that they will collaborate to develop, manufacture and distribute the respiratory drug LAS100977.
The inhaled, once-daily treatment is a long-acting beta-agonist that has been developed by Almirall to treat bronchoconstriction in asthmatic patients.
Now, the firm will work with Forest to develop the treatment in combination with an undisclosed corticosteroid using Almirall's proprietary Genuair inhaler for the treatment of both asthma and chronic obstructive pulmonary disease.
Jorge Gallardo, chairman and chief executive officer of Almirall, said: "Extending our collaboration with Forest is an excellent opportunity to maximise the value of LAS100977 for patients and investors."
Meanwhile, last week the organisation launched two new treatments for people who suffer from arterial hypertension.
These are Parapres Plus 32 and Parapres Plus Forte, which are indicated for patients with high blood pressure that cannot be sufficiently controlled with monotherapy.Other news stories from 21/12/2009
Read more in the Zenopa News Archive
How this news is generated
|
